The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials. [PDF]
Wu Z +5 more
europepmc +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of <i>Clostridioides difficile</i> Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs. [PDF]
Omar MA +6 more
europepmc +1 more source
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi +100 more
wiley +1 more source
Proton Pump Inhibitor Use in Patients With Cirrhosis and Its Association With Spontaneous Bacterial Peritonitis. [PDF]
Thomas M, Lanier C, Covert K.
europepmc +1 more source
Although physiologically based pharmacokinetic (PBPK) modeling is increasingly being used to support oral drug formulation bridging, the acceptance by regulatory agencies is low. One of the primary concerns is the absence of clinical pharmacokinetic (PK) data from a non‐bioequivalent (non‐BE) batch during model validation.
Jin Dong +6 more
wiley +1 more source
Proton pump inhibitor increases intestinal epithelial paracellular permeability via the p38-MAPK/NF-κB signaling pathway. [PDF]
Zhang M +8 more
europepmc +1 more source
CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park +2 more
wiley +1 more source
Proton pump inhibitor use and cardiovascular risk, all-cause, and cardiovascular mortality across baseline eGFR categories: a longitudinal study. [PDF]
Zhang T, Li T, Jin P.
europepmc +1 more source
PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory +13 more
wiley +1 more source

